Author | Treatment regimen | No. of patients | Gastrointestinal toxicity (≥ Grade 3) | Hematologic toxicity (≥ Grade 3) | Local failure rate | Median PFS (months) | Median OS (months) |
---|---|---|---|---|---|---|---|
Cohen et al.[7] | RT 59.4 Gy/5-FU+mitomycin | 55 | 13% | 20% | NA | 5.1 | 8.4 |
Ishii et al.[8] | RT 50.4 Gy/5-FU | 20 | 15% | 0% | 35% | 4.9 | 10.3 |
Kornek et al.[9] | RT 55 Gy/5-FU+cisplatin | 38 | 18% | 18% | NA | 10 | 14 |
Boz et al.[10] | RT 59.4 Gy/5-FU | 42 | 4% | 16% | 51% | 6.2 | 9.1 |
Magnino et al.[12] | RT 45 Gy/GEM | 23 | 30% | 39% | 22% | NA | 12 |
Blackstock et al.[13] | RT 50.4 Gy/GEM | 39 | 41% | 69% | 15% | NA | 7.9 |
Okusaka et al.[14] | RT 50.4 Gy/GEM | 38 | 33% | 52% | 6% | 4.4 | 9.5 |
Li et al.[15] | RT 50.4-61.2 Gy/GEM | 18 | 28% | 28% | 34% | 7.1 | 14.5 |
Murphy et al.[16] | *RT 36 Gy/GEM | 74 | 11% | 24% | 26% | NA | 11.2 |
This study | *RT 50 Gy/5-FU | 10 | 0% | 17% | 8% | 7.6 | 12.1 |